Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DH Stock Forecast 2026-2027
$0.95
Current Price
$100.47M
Market Cap
Buy 3
Hold 8
Sell 1
Wall St Analyst Ratings
Distance to DH Price Targets
+267.3%
To High Target of $3.50
+188.6%
To Median Target of $2.75
+4.9%
To Low Target of $1.00
DH Price Momentum
-7.8%
1 Week Change
0.0%
1 Month Change
-74.3%
1 Year Change
-66.9%
Year-to-Date Change
-79.7%
From 52W High of $4.70
+6.5%
From 52W Low of $0.89
📊 TOP ANALYST CALLS
Did DH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Definitive Healthcare is one of their latest high-conviction picks.
Latest DH Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, DH has a neutral consensus with a median price target of $2.75 (ranging from $1.00 to $3.50). The overall analyst rating is Buy (6.8/10). Currently trading at $0.95, the median forecast implies a 188.6% upside. This outlook is supported by 3 Buy, 8 Hold, and 1 Sell ratings.
Conversely, the most conservative target is provided by Saket Kalia at Barclays, suggesting a 4.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DH Analyst Ratings
3
Buy
8
Hold
1
Sell
DH Price Target Range
Low
$1.00
Average
$2.75
High
$3.50
Current: $0.95
Latest DH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 30, 2026 | Barclays | Saket Kalia | Underweight | Maintains | $1.00 |
| Feb 27, 2026 | Canaccord Genuity | David Hynes | Hold | Maintains | $3.00 |
| Feb 27, 2026 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $2.00 |
| Dec 9, 2025 | Barclays | Saket Kalia | Underweight | Maintains | $2.75 |
| Nov 10, 2025 | Canaccord Genuity | David Hynes | Hold | Maintains | $4.00 |
| Aug 8, 2025 | Stifel | David Grossman | Buy | Maintains | $6.00 |
| May 12, 2025 | Goldman Sachs | Kash Rangan | Neutral | Maintains | $3.40 |
| Mar 4, 2025 | Goldman Sachs | Kash Rangan | Neutral | Maintains | $3.00 |
| Mar 3, 2025 | Barclays | Saket Kalia | Underweight | Maintains | $3.00 |
| Jan 16, 2025 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Jan 13, 2025 | Barclays | Saket Kalia | Underweight | Downgrade | $4.00 |
| Dec 20, 2024 | Stephens & Co. | Equal-Weight | Initiates | $N/A | |
| Nov 8, 2024 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Sep 17, 2024 | BTIG | David Larsen | Buy | Initiates | $7.00 |
| Aug 9, 2024 | Deutsche Bank | George Hill | Hold | Maintains | $5.00 |
| Aug 7, 2024 | Barclays | Saket Kalia | Equal-Weight | Maintains | $4.00 |
| Aug 7, 2024 | Baird | Vikram Kesavabhotla | Neutral | Maintains | $5.00 |
| Aug 6, 2024 | Needham | Ryan MacDonald | Hold | Reiterates | $N/A |
| Aug 6, 2024 | Morgan Stanley | Craig Hettenbach | Equal-Weight | Maintains | $5.00 |
| Jul 31, 2024 | Baird | Vikram Kesavabhotla | Neutral | Maintains | $6.00 |
Definitive Healthcare Corp. (DH) Competitors
The following stocks are similar to Definitive Healthcare based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DH
Definitive Healthcare
mkt cap
100.47M
Definitive Healthcare Corp. (DH) Financial Data
Valuation Metrics
Market Cap
$100.47M
Enterprise Value
$136.59M
P/E Ratio
N/A
PEG Ratio
5.0x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-5.5%
Gross Margin
+76.2%
Operating Margin
-8.6%
Net Margin
-71.5%
EPS Growth
-1.2%
Financial Health
Cash/Price Ratio
+177.2%
Current Ratio
1.8x
Debt/Equity
89.1x
ROE
-75.5%
ROA
-1.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Definitive Healthcare Corp. (DH) Business Model
About Definitive Healthcare Corp.
What They Do
Provides healthcare commercial intelligence via software.
Business Model
The company operates a cloud-based, subscription-based software platform that aggregates diverse healthcare data to provide insights for life sciences companies, healthcare providers, payers, and consulting firms. It generates revenue primarily through subscription fees from users who leverage its platform for market analysis, strategic planning, and operational improvements.
Additional Information
Founded in 2011 and headquartered in Framingham, Massachusetts, the company focuses on the U.S. market and offers detailed profiles of healthcare entities, enabling data-driven decision-making. Its comprehensive data sources include claims data and proprietary research, positioning it as a key player in the healthcare intelligence sector.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
678
CEO
Mr. Kevin D. Coop
Country
United States
IPO Year
2021
Website
www.definitivehc.comDefinitive Healthcare Corp. (DH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Definitive Healthcare Corp. (DH) Tops Q1 Earnings Estimates
Definitive Healthcare (DH) delivered earnings and revenue surprises of +100.00% and -24.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2026
By Zacks Equity Research
Tale of the Tape
Teradata (TDC) Tops Q1 Earnings and Revenue Estimates
Teradata (TDC) delivered earnings and revenue surprises of +14.29% and +4.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 05, 2026
By Zacks Equity Research
Tale of the Tape
Docebo Inc. (DCBO) Reports Next Week: Wall Street Expects Earnings Growth
Docebo (DCBO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
May 01, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Definitive Healthcare Corp. (DH) held its Q1 2026 earnings call, discussing financial performance and strategic developments. Further details on earnings and projections were shared.
Why It Matters
Earnings calls provide insights into a company's financial health and future outlook, influencing investment decisions and stock performance. Key metrics and guidance impact valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Definitive Healthcare Corp. (Nasdaq: DH) announced its financial results for Q1 2026, ending March 31. Further details on performance are pending in the full report.
Why It Matters
Definitive Healthcare's quarterly financial results provide insights into its performance, impacting stock valuation and investor sentiment in the healthcare data analytics sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Definitive Healthcare Corp. (DH) reported Q3 earnings of $0.06 per share, exceeding the Zacks Consensus Estimate of $0.03, and up from $0.05 per share year-over-year.
Why It Matters
Definitive Healthcare's earnings beat estimates, signaling stronger performance and growth potential, which could positively influence investor sentiment and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Analysts Estimate Definitive Healthcare Corp. (DH) to Report a Decline in Earnings: What to Look Out for
11 days ago
Quick Summary
Definitive Healthcare (DH) is expected to lack the necessary factors for a potential earnings beat in its upcoming report, according to recent analysis.
Why It Matters
Definitive Healthcare's lack of key earnings indicators may signal potential underperformance, impacting stock price and investor sentiment ahead of the earnings report.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Definitive Healthcare Corp. (Nasdaq: DH) will report Q1 2026 financial results on May 7, 2026, after market close, followed by a conference call at 5 PM ET.
Why It Matters
Definitive Healthcare's upcoming Q1 financial results announcement could impact stock performance, influencing investor sentiment and trading decisions based on earnings expectations.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Oversold stocks in the health care sector may offer investment opportunities in undervalued companies.
Why It Matters
Oversold health care stocks may indicate potential for price recovery, offering investors a chance to capitalize on undervalued assets for future gains.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About DH Stock
What is Definitive Healthcare Corp.'s (DH) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Definitive Healthcare Corp. (DH) has a median price target of $2.75. The highest price target is $3.50 and the lowest is $1.00.
Is DH stock a good investment in 2026?
According to current analyst ratings, DH has 3 Buy ratings, 8 Hold ratings, and 1 Sell ratings. The stock is currently trading at $0.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DH stock?
Wall Street analysts predict DH stock could reach $2.75 in the next 12 months. This represents a 188.6% increase from the current price of $0.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Definitive Healthcare Corp.'s business model?
The company operates a cloud-based, subscription-based software platform that aggregates diverse healthcare data to provide insights for life sciences companies, healthcare providers, payers, and consulting firms. It generates revenue primarily through subscription fees from users who leverage its platform for market analysis, strategic planning, and operational improvements.
What is the highest forecasted price for DH Definitive Healthcare Corp.?
The highest price target for DH is $3.50 from at , which represents a 267.3% increase from the current price of $0.95.
What is the lowest forecasted price for DH Definitive Healthcare Corp.?
The lowest price target for DH is $1.00 from Saket Kalia at Barclays, which represents a 4.9% increase from the current price of $0.95.
What is the overall DH consensus from analysts for Definitive Healthcare Corp.?
The overall analyst consensus for DH is neutral. Out of 17 Wall Street analysts, 3 rate it as Buy, 8 as Hold, and 1 as Sell, with a median price target of $2.75.
How accurate are DH stock price projections?
Stock price projections, including those for Definitive Healthcare Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 10:19 AM UTC